Ferrer Internacional, S.a.

Ferrer International, S.a.

Bioprojet

Manuel M Raga

Rafael Foguet

Antonio Guglietta

Jose A Ortiz

Josep M Castello

Aurelio Sacristan

Jorge Ramentol

Juan Sallares

Benjamin Santos

José A Ortiz

Rafael Lozano

Jean-Charles Schwartz

Jeanne-Marie Lecomte

Xavier Ligneau

Walter Schunack

Jean-Michel Arrang

Holger Stark

Santiago Gubert

Marta Guerrero

Jose M Castello

Cristina Tarragó

Isidro J Ferrer

Julio J Secades

Charon Ganellin

Luis Anglada

Lluis Anglada

Inés Petschen

Diego Fernandez-Cano

Miguel P Armengol

Francesc X Camps

Rosa M Cuberes

Marcial Moreno

Jordi Teixidó

Jesús Torres

Julián Agut

Ricardo Miralles

Santiago Nonell

Antonio Giuglietta

Jordi Teixido

Jordi TeixidÓ

The invention provides pharmaceutical stable semisolid topical compositions comprising between 0.2 to 5% of a des-fluoroquinolone compound, and a suitable carrier to manufacture an ointment or a cream.

Pharmaceutical topical compositions

Benzoic acid ester compounds of formula (I): wherein R and R-Rhave the meanings explained in the description, methods for producing them and use thereof in cosmetic, pharmaceutical, personal care and industrial preparations as sunscreens based on photochemical precursor properties of ultraviolet absorbers.

Benzoic acid ester compounds, compositions, uses and methods related thereto

A method is provided for the treatment of sleep apnea and other conditions wherein an effective amount of crystalline 1-[3-[3-(4-chlorophenyl)propoxy]propyl]-piperidine monohydrochloride of formula (I): optionally comprising water up to 6%, and having an X-ray diffractogram that comprises characteristic peaks (2&#x3b8;) at 11.2&#xb0;, 19.9&#xb0;, 20.7&#xb0; and 34.1&#xb0;&#xb1;0.2&#xb0; is administered to a patient in need thereof.

Monohydrochloride salt of 1-[3-[3-(4-chlorophenyl) propoxy]propyl]-piperidine

The invention relates to new crystalline 1-[3-[3-(4-chlorophenyl)propoxy]propyl]-piperidine monohydrochloride, the respective manufacture and methods of use, and compositions containing such a compound.

Monohydrochloride salt of 1-[3-[3-(4-chlorophenyl) propoxy] propyl] -piperidine

The invention describes a prophylactic treatment of cerebral ischemia with CDP-Choline in patients who have undergone major surgery or are at risk of suffering an acute ischemic event.

Use of CDP-choline for the prophylactic treatment of cerebral ischemia

The invention describes the prophylactic treatment of cerebral ischemia with CDP-Choline in patients who have undergone major surgery or are at risk of suffering an acute ischemic event.

The invention relates to the use of CDP-Choline or its pharmaceutically acceptable salts for the preparation of a medicinal product for the treatment of alcohol withdrawal syndrome at daily doses equivalent to 0.5-2 g of free CDP-Choline.

Use of CDP-choline for the treatment of alcohol withdrawal syndrome

The present invention relates to a process for preparing (&#xb1;)-trans-4-p-fluorophenyl-3-hyroxymethyl-1-methylpiperdine of formula (I). The present invention also relates to novel intermediates of the formula (IX) and (IX') methods for preparing said intermediates and the use of said compounds for preparing Paroxetine and Omiloxetine.

Process for preparing (&#xb1;)trans-4-p-fluorophenyl-3-hydroxymethyl-1-methylpiperidine

Polymorphs B and C of

The 1H-imidazole derivative compound of formula I: ##STR1## and its nontoxic addition salts, particularly the nitrate addition salt, are more effective as antimycotic agents and are unexpectedly safer than the corresponding prior art compounds, especially the compound in which the sulfur atom of the benzothiophene ring of the above compound is replaced by an oxygen atom. Pharmaceutical compositions containing an effective amount of the compound of formula I, e.g. 1 to 5% by weight, in a pharmaceutical carrier are safer, more effective, and, in some cases, more reliable with fewer side effects than currently used antimycotic preparations.

1H-imidazole derivative compounds and pharmaceutical compositions

Derivatives of piperazine having the general formula ##STR1## wherein R.sub.1 is benzhydryl or cinnamyl and R.sub.2 is selected from the group consisting of ##STR2## --(CH.sub.2).sub.3 --R.sub.8, --CH.sub.2 NHR.sub.9, --CH.sub.2 NH.sub.2 and --COR.sub.10 ; wherein R.sub.3 is hydrogen, chloromethyl, (4-benzhydryl-1-piperazinyl) methyl, 4-morpholinylmethyl or 1-piperidinylmethyl, R.sub.4 is hydrogen, chloromethyl or carbethoxy, R.sub.5 and R.sub.6 taken together are an oxygen atom or the radical --O--(CH.sub.2).sub.2 --O--, R.sub.7 is methyl, phenyl or 2-thienyl, R.sub.8 is 4-morpholinyl, 1-piperidinyl or 4-benzhydryl-1-piperazinyl, R.sub.9 is 2-oxo-1- (pyrrolidinyl) acetyl, 2-hydroxybenzoyl or 4-sulfamoylbenzoyl, R.sub.10 is 2-oxo-1-(pyrrolidinyl)methyl or 4-sulfamoylphenyl and X is oxygen or NH; as well as methods for making the same and their use in a pharmaceutical composition is proposed. The compounds have cardiovascular properties and increasing effects on cerebral flow.

Derivatives of piperazine, method for making the same

A piperazine derivative is disclosed of formula (I): ##STR1## and the non-toxic addition salts thereof, along with a process for preparation, pharmaceutical composition, and method of treating conditions characterized by histamine activity.

Piperazine derivative and pharmaceutical composition containing the same

New N-cyano-formamidine are disclosed of the formula I: ##STR1## wherein R is 2-[[(5-methyl-1H-Imidazol-4-yl)methyl]thio]ethyl, 2-[[[5-[dimethylamino)methyl]-2-furanyl]methyl]thio]ethyl, 2-[[[2-[(aminoiminomethyl)amino]-4-thiazolyl]methyl]thio]ethyl or 3-[3-(1-piperidinylmethyl)phenoxy]propyl, as well as a process for its production, and pharmaceutical preparations containing the same. The compounds possess histamine--induced gastric acid secretion--inhibiting activity, and are indicated for use in the treatment of peptic ulcer and other pathologies caused or stimulated by gastric acidity.

N-cyano-formamidines

Growing community of inventors

Barcelona, Spain

Manuel M Raga